There is an urgent and currently unmet need to provide robust information that can inform risk management strategies for carriers of pathogenic variants in intermediate risk genes such as ATM and CHEK2, as these genes are now routinely included on gene panels for cancer predisposition. Here, CHEK2 is linked to cancer.